However, two cases of cardiotoxicity were reported with the use of high-affinity T-cell receptors against melanoma antigen family A, 3 (MAGE-A3) in the treatment of melanoma and myeloma. This evidence concerns the gene MAGEA3 and plasma cell myeloma.